JACKSONVILLE, Fla.--(BUSINESS WIRE)--NovaBone Products, a leading biologics medical device company, today announces the U.S. Food and Drug Administration’s (FDA) approval of the NovaBone MacroFORM MIS Delivery System™ designed for use in minimally invasive orthopedic procedures.
“We continue to reach milestones we have established”
For the first time, surgeons can directly deliver Bone Marrow Aspirate (BMA) to a graft which is housed in a closed, ready to use minimally invasive cannula. The system was developed for surgeons who require controlled and precise delivery of bone grafting material to surgical sites that are not readily accessible.
“The MacroFORM MIS Delivery System™ builds off the commercial success of the intuitively-designed collagen devices we have launched over the past several months,” said Dennis McBride, Vice President of Sales and Marketing. “Moreover, NovaBone’s MacroFORM™ technology, which offers more bioactivity than any other competitive product, is now available in multiple formulations, and delivery options.”
NovaBone Products has announced release of six new collagen products in the last twelve months; the devices are based on the company’s regenerative medicine technology and core competencies in designing innovative and cost-effective medical devices that meet the demands of surgeons. NovaBone now has the broadest offering of bone graft substitutes in the world.
“We continue to reach milestones we have established," said Art Wotiz, President of NovaBone Products. ”Our team has done an excellent job in terms of both design and manufacturing of collagen products and creating a robust pipeline of products that harness the natural healing process of the body.”
NovaBone Products, a privately held company based in Florida, USA since 2002 and a recognized industry leader in bioactive glass design and manufacturing, developed the first bioactive synthetic bone graft offered to the orthopaedic community.